{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-24-000193","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.111131+00:00","generated_at":"2026-05-31T14:09:39.742277+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Vertex Q2 product revenue $2.65B (+6% YoY); raises FY 2024 guidance to $10.65-10.85B","bullets":["GAAP net loss of $3.6B in Q2 due to $4.4B AIPR&D charge from Alpine acquisition.","Non-GAAP net loss of $3.3B; combined R&D and SG&A expenses increased to $1.3B.","FDA accepted NDAs for vanzacaftor triple (PDUFA Jan 2, 2025) and suzetrigine (PDUFA Jan 30, 2025).","CASGEVY launches ongoing; >35 ATCs activated; early access program in France for SCD.","Year-end cash $10.2B vs $13.7B end of 2023; cash used for Alpine acquisition."],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-24-000193","json":"https://secwatch.observer/filing/0000875320-24-000193.json","markdown":"https://secwatch.observer/filing/0000875320-24-000193.md","text":"https://secwatch.observer/filing/0000875320-24-000193.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000193/0000875320-24-000193-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000193/vrtx-20240801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:09:39.742277+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}